Evolus (NASDAQ:EOLS) Stock Price Down 5.7% - Here's Why

Evolus, Inc. (NASDAQ:EOLS - Get Free Report)'s stock price was down 5.7% during trading on Monday . The stock traded as low as $11.13 and last traded at $10.99. Approximately 154,100 shares changed hands during trading, a decline of 77% from the average daily volume of 665,766 shares. The stock had previously closed at $11.65.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on EOLS shares. BTIG Research initiated coverage on Evolus in a research note on Thursday, April 17th. They issued a "buy" rating and a $21.00 price objective on the stock. Needham & Company LLC reaffirmed a "buy" rating and issued a $22.00 price objective on shares of Evolus in a research report on Wednesday, April 9th. Barclays boosted their target price on shares of Evolus from $22.00 to $25.00 and gave the stock an "overweight" rating in a research report on Wednesday, March 5th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $27.00 price target on shares of Evolus in a report on Thursday, April 10th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Evolus has a consensus rating of "Buy" and an average price target of $23.75.

Evolus Stock Performance

The company has a debt-to-equity ratio of 20.58, a quick ratio of 2.23 and a current ratio of 2.47. The company has a market capitalization of $720.76 million, a price-to-earnings ratio of -12.46 and a beta of 0.97. The company's fifty day simple moving average is $12.25 and its two-hundred day simple moving average is $12.90.

Insider Transactions at Evolus

In related news, Director Karah Herdman Parschauer sold 12,888 shares of the stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $12.99, for a total value of $167,415.12. Following the sale, the director now owns 32,183 shares of the company's stock, valued at $418,057.17. This trade represents a 28.59 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider David Moatazedi sold 6,251 shares of the business's stock in a transaction dated Thursday, March 27th. The shares were sold at an average price of $12.40, for a total transaction of $77,512.40. Following the transaction, the insider now directly owns 508,619 shares of the company's stock, valued at $6,306,875.60. The trade was a 1.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 60,575 shares of company stock worth $794,369. 6.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Evolus

Hedge funds and other institutional investors have recently made changes to their positions in the business. KBC Group NV bought a new position in shares of Evolus in the fourth quarter worth $49,000. IFP Advisors Inc raised its position in shares of Evolus by 17,440.7% during the 4th quarter. IFP Advisors Inc now owns 4,736 shares of the company's stock worth $52,000 after buying an additional 4,709 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new stake in shares of Evolus in the 4th quarter worth approximately $106,000. Rafferty Asset Management LLC acquired a new position in shares of Evolus during the fourth quarter valued at approximately $115,000. Finally, Quantbot Technologies LP bought a new stake in Evolus during the fourth quarter worth approximately $118,000. 90.69% of the stock is currently owned by institutional investors and hedge funds.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.